Feature Papers in Allergic Diseases

A special issue of Medicines (ISSN 2305-6320). This special issue belongs to the section "Allergic Diseases".

Deadline for manuscript submissions: closed (31 May 2021) | Viewed by 4041

Special Issue Editor


E-Mail Website
Guest Editor
Faculty of Human Sciences, University of Human Arts and Sciences, Iwatsuki-ku, Saitama 339-8555, Japan
Interests: inflammation; mMucosal immunity; nasal Allergy; histamine H1 receptor antagonists; macrolide antibiotics; immunomodulation of natural products

Special Issue Information

Dear colleagues,

I am pleased to announce our upcoming Special Issue entitled "Feature Papers in Allergic Diseases". This Special Issue will publish high-quality articles (original research and review articles) on key topics relating to all aspects of allergic diseases. This Special Issue aims to discuss new knowledge in allergic diseases and to disseminate excellent research findings as well as sharing innovative ideas in this field.

I look forward to reviewing your submissions.

Prof. Dr. Kazuhito Asano
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • allergic rhinitis
  • asthma
  • atopic dermatitis
  • epidemiology of allergic diseases
  • treatment and prevention of allergic diseases
  • mucosal inflammation
  • inflammatory cytokines

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 8235 KiB  
Article
Inhibition of Angiogenic Factor Productions by Quercetin In Vitro and In Vivo
by Takayuki Okumo, Atsuko Furuta, Tarou Kimura, Kanako Yusa, Kazuhito Asano and Masataka Sunagawa
Medicines 2021, 8(5), 22; https://doi.org/10.3390/medicines8050022 - 12 May 2021
Cited by 7 | Viewed by 3581
Abstract
Background: Angiogenesis is well known to be an important event in the tissue remodeling observed in allergic diseases. Although there is much evidence that quercetin, one of the most abundant dietary flavonoids, exerts anti-allergic effects in both human and experimental animal models of [...] Read more.
Background: Angiogenesis is well known to be an important event in the tissue remodeling observed in allergic diseases. Although there is much evidence that quercetin, one of the most abundant dietary flavonoids, exerts anti-allergic effects in both human and experimental animal models of allergic diseases, the action of quercetin on angiogenesis has not been defined. Therefore, in this study, we first examined the action of quercetin on the secretion of angiogenic factors from murine mast cells in vitro. We also examined the action of quercetin on angiogenic factor secretion in the murine allergic rhinitis model in vivo. Methods: Mast cells (1 × 105 cells/mL) sensitized with ovalbumin (OVA)-specific murine IgE were stimulated with 10.0 ng/mL OVA in the presence or the absence of quercetin for 24 h. The concentrations of angiogenic factors, vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), tumor necrosis factor-α, IL-6 and IL-8 in the supernatants were examined by ELISA. BALB/c male mice immunized with OVA were challenged intranasally with OVA every other day, starting seven days after the final immunization. These mice were then orally administered quercetin once a day for five days, starting seven days after the final immunization. Clinical symptoms were assessed by counting the number of sneezes and nasal rubbing behaviors during the 10 min period just after OVA nasal provocation. The angiogenic factor concentrations in the nasal lavage fluids obtained 6 h after nasal antigenic provocation were examined by ELISA. Results: Quercetin significantly inhibited the production of angiogenetic factors induced by IgE-dependent mechanisms at 5.0 µM or more. Oral administration of 25.0 mg/kg quercetin into the mice also suppressed the appearance of angiogenetic factors in nasal lavage fluids, along with the attenuation of nasal symptoms. Conclusions: These results strongly suggest that the inhibitory action of quercetin on angiogenic factor secretion may be implicated in the therapeutic action of quercetin on allergic diseases, especially allergic rhinitis. Full article
(This article belongs to the Special Issue Feature Papers in Allergic Diseases)
Show Figures

Figure 1

Back to TopTop